Antibody therapeutics for Ebola virus disease.

Authors :: Zeitlin L
Whaley KJ
Olinger GG
Jacobs M
Gopal R
Qiu X
Kobinger GP
Source :: Current opinion in virology [Curr Opin Virol] 2016 Apr; Vol. 17, pp. 45-49. Date of Electronic Publication: 2016 Jan 27.
Publication Year :: 2016
Abstract: With the unprecedented scale of the 2014-2016 West Africa outbreak, the clinical and scientific community scrambled to identify potential therapeutics for Ebola virus disease (EVD). Passive administration of antibodies has a long successful history for prophylaxis and therapy of a variety of infectious diseases, but the importance of antibodies in EVD has been unclear and is the subject of some debate. Recent studies in non-human primates have renewed interest in the potential of antibodies to impact EVD. Currently ongoing clinical evaluation of polyclonal and monoclonal antibody therapy in EVD patients in West Africa may finally offer a definitive answer to this debate.<br /> (Copyright © 2016 Elsevier B.V. All rights reserved.)